Usefully understood as digitizing bioprocessing. Bitome's AI engine leverages metabolomics rapidly to accelerate process optimization: helping biotech companies get product to market faster. In June 2022 it was announced that Ginkgo Bioworks (NYSE: DNA) - also an SBIR involved firm - and the leading horizontal platform for cell programming,had acquired certain assets from Bitome, a company pioneering real-time metabolite monitoring for faster biological product development. Bitome has developed technology leveraging machine learning to provide continuous monitoring of cell culture media, illuminating the performance of cells in real-time and enabling faster rates of bioprocess optimization.A life science instrument company, Bitome is a medical device, health diagnostics entity addressing development of compact, portable chemical analysis tools designed for use in magnetic resonance spectroscopy. Using microsystem technology compatible with scaled manufacturing processes, Bitome is structured around delivering cost-efective, game-changing life science research tools. The firm's first product provides continuous metabolic monitoring in synthetic biology applications: a noninvasive tool for monitoring hydration status with broad applications across the dialysis, diabetic, sports performance, and maternal / fetal monitoring spaces. Employing hydration monitoring technology to do for Conjestive Heart Failure (CHF) what glucose monitoring has done for diabetes. in a first application, Bitomeâs technology is designed precisely to assess volume status in CHF patients â a key, but hard to measure, biometric correlated with patient outcom
